Zai Lab has granted approximately 170,000 restricted shares under the 2024 stock-based incentive plan.
Zai Lab (09688) announced that on June 18, 2024, the company granted restricted shares involving a total of 170,024 shares of American depositary shares to 8 grant holders under the 2024 stock-based incentive plan.
Zai Lab (09688.HK) granted 170,000 restricted shares.
Zai Lab (09688.HK) announced on June 19th that the Board of Directors hereby announces that on June 18th, 2024 (Eastern Time of the United States), the company granted 170,024 restricted shares of American Depositary Shares involving eight grantees under the 2024 stock-based incentive plan.
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading
Asian equities traded in the US as American depositary receipts were trending lower Friday morning, declining 0.9% to 1,933.52 on the S&P Asia 50 ADR Index. The index is down 0.5% for the week so far.
Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)
J.P. Morgan Maintains Zai Lab(ZLAB.US) With Buy Rating, Announces Target Price $43
J.P. Morgan analyst Anupam Rama maintains $Zai Lab(ZLAB.US)$ with a buy rating, and sets the target price at $43.According to TipRanks data, the analyst has a success rate of 45.5% and a total average
It's Unlikely That Zai Lab Limited's (NASDAQ:ZLAB) CEO Will See A Huge Pay Rise This Year
Key Insights Zai Lab to hold its Annual General Meeting on 18th of June Salary of US$868.5k is part of CEO Samantha Du's total remuneration The overall pay is 68% above the industry average Zai
Express News | Zai Lab Ltd : JP Morgan Raises Target Price to $43 From $38
Harald Reinhart, the global head of development for central nervous system, autoimmune and infectious diseases at Zai Lab (09688), is about to retire.
Zai Lab (09688) announced that Dr. Harald Reinhart, the global head of central nervous system, autoimmunity, and infectivity disease(NSAiID) development, and CEO of Zai Lab will retire and serve as senior advisor of the company by the end of June, after completing his outstanding career. After his retirement, the scope of Dr. Rafael Amado, the global head of oncology research and CEO of Zai Lab will expand and he will be responsible for all global research and development work of the company.
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to Be Appointed President, Head of Global R&D
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
Express News | Zai Lab Announces DR. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; DR. Rafael Amado to Be Appointed President, Head of Global R&D
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
BofA Securities analyst David Li maintains $Zai Lab(ZLAB.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 17.1% and a total a
Express News | JPMorgan Chase & Co's Long Position in Zai Lab Decreases to 12.76% on June 4 From 13.57% - HKEX
Hong Kong stock market anomaly: Zai Lab (09688) rose nearly 4%, granting a total of 2200 American Depositary Shares of stock-based incentive plan.
Zai Lab (09688) has risen nearly 4%, as of press time, up 3.85%, at HKD 15.640 with a turnover of HKD 26,812,000.
Zai Lab (09688) has granted stock options for a total of 2200 American depositary shares under the 2022 stock-based incentive plan.
Zai Lab (09688) released an announcement on June 3, 2024 (Eastern Time in USA), the company based on 20...
Zai Lab (09688.HK) has granted purchase options and restricted stock units.
On June 6th, Gelunhui announced that Zai Lab (09688.HK) granted stock options for a total of 2,200 American depositary shares to one grantee in accordance with the 2022 stock-based incentive plan, and granted restricted stock units involving a total of 3,600 American depositary shares to two grantees on June 3rd, 2024 (US Eastern Time).
Zai Lab (09688.HK) received 6,693,200 shareholdings from JPMorgan.
According to the latest equity disclosure information from the Stock Exchange, on May 30, 2024, Zai Lab (09688.HK) received JPMorgan Chase & Co.'s shareholding of 6,693,200 shares at an average price of HKD 13.7709 per share, involving approximately HKD 92.1711 million. After the shareholding, the latest shareholding of JPMorgan Chase & Co. increased from 12.79% to 13.46%, with a total of 133,582,445 shares.
Zai Lab (09688.HK) received a shareholding increase of 15,488,600 shares from Wellington Management Group LLP.
According to the latest equity disclosure data from the HKEX on June 5th, 2024, Zai Lab (09688.HK) received shareholding from Wellington Management Group LLP of 15.48 million shares at an average price of HK$14.544 per share, with a total investment of approximately HK$225 million. After the shareholding, Wellington Management Group LLP now holds 107,384,700 shares, and their shareholding percentage has increased from 9.26% to 10.82%.
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial results.Core & Main posted quarterly earnings of 49 cents per share,
Qiming's Nisa Leung Made the 2024 Forbes Midas List
The 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung, Managing...
U.S. stock anomaly|Chinese pharmaceutical stocks rise, hutchmed (china) (HCM.US) rose more than 5%.
Chinese pharmaceutical stocks have risen, and as of press time, Hutchmed (China) has risen over 5%.
No Data